Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia

J Infect Public Health. 2018 Nov-Dec;11(6):793-795. doi: 10.1016/j.jiph.2018.04.013. Epub 2018 Apr 26.

Abstract

Introduction: Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide.

Cases and managements: This case-series describes our experience with ceftazidime-avibactam in the treatment of six cases with carbapenem-resistant organisms in King Abdulaziz Medical City in Riyadh, Saudi Arabia. After trying various combinations of antibiotic therapies without improvement, cases were treated with ceftazidime-avibactam.

Outcomes: Five of the six achieved complete cure, both clinically and microbiologically.

Keywords: Ceftazidime–avibactam; MDR-infections; Saudi Arabia.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Azabicyclo Compounds / therapeutic use*
  • Ceftazidime / therapeutic use*
  • Drug Combinations
  • Gram-Negative Bacterial Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Saudi Arabia
  • Tertiary Care Centers
  • Treatment Outcome
  • beta-Lactamase Inhibitors / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • beta-Lactamase Inhibitors
  • Ceftazidime